Latest fiscal year 2023 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2023, NovaBridge Biosciences reported revenue of $1M, down 140.7% year over year. Operating margin was -11395.1% and net margin -32868.5%, on a free-cash-flow margin of -29107.9% with capital expenditure at 25.9% of revenue. Every figure is computed directly from NBP's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2023 | $1M | -11395.1% | -32868.5% |
| FY2022 | $-2M | 3422.2% | 23923.5% |
| FY2021 | $14M | n/a | -2648.7% |
| FY2020 | $236M | n/a | 30.5% |
How does NBP compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.